Postoperative Pain ManagementPhase 3NCT07186426
A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain Treatment in Orthopedic Surgery
A Phase 3 study testing HSK21542 and morphine in people with Postoperative Pain Management, run by Haisco Pharmaceutical Group Co., Ltd. at 2 sites in China.
Trial summary
This is a multi-center, randomized, double-blind, placebo/active-controlled study. 405 subjects undergoing orthopedic surgery under general anesthesia are planned to be enrolled and randomized into the HSK21542 group, morphine group, and placebo group. Read more about this study
- Who is it for?
- Ages 18 to 74 years
- Conditions the study is for
- Postoperative Pain Management
- What is being tested?
- HSK21542 and morphine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 405 participants
- Where
- 2 sitesChina
- Study dates
- 5 Aug 2025to 24 Feb 2026
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 74 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 18 years old ≤ age ≤74 years old, regardless of gender;
- 18 kg/m2≤BMI≤32 kg/m2，meet the weight range specified in the protocol；
- American Society of Anesthesiologists (ASA) grade ⅰ-ⅲ;
- Accept hip replacement under general anesthesia;
- Within 4 hours after the end of surgery, NRS≥4 in the resting state at any time;
- Fully understand and voluntarily participate this trial, and sign the informed consent form;
Who cannot join
- Patients with allergy to opioids or any component of the trial drug；
- Patients with a history of severe cardiovascular and cerebrovascular diseases, ,and psychiatric disorders;
- Last use of opioid or non-opioid analgesics less than 5 half-lives or the duration of drug efficacy prior to randomization; use of drugs with unclear half-lives that may affect analgesic efficacy within 7 days prior to randomization, or last use of drugs affecting analgesic efficacy less than 5 half-lives prior to randomization, as well as Chinese herbal medicines or proprietary Chinese medicines deemed by the investigator as potentially impacting the evaluation of efficacy and safety；
- Continuous use of opioid analgesics for more than 7 days for any reason within 30 days prior to screening;
- Laboratory test results during the screening period meeting any of the following criteria: 1) Significantly abnormal hematology results; 2) Significantly abnormal prothrombin time test results; 3) Significantly abnormal liver or kidney function; 4) Significantly abnormal fasting blood glucose;
- Positive test results during the screening period for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), syphilis antibody, or human immunodeficiency virus (HIV) antibody;
Show all 11Show fewer
- A history of drug, drug, and/or alcohol abuse；
- Participate in any clinical trail within 30 days;
- Pregnant or lactating female subjects；
- Subjects of childbearing potential who are unwilling to use contraception throughout the study period or plan to become pregnant within 3 months after the study.；
- Subjects with any other factor considered by the investigator to be ineligible for participation in the trial.
Trial locations and contacts
2 sites in 1 country.
China2 sites
Xuanwu Hospital Capital Medical University
Beijing, Beijing Municipality
Xiangya Hospital of Central South University
Changsha, Hunan
About this study
Official title: A Multi-Center, Randomized, Double-Blind, Placebo/Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HSK21542 Injection for Postoperative Pain Treatment in Orthopedic Surgery
This is a multi-center, randomized, double-blind, placebo/active-controlled study. 405 subjects undergoing orthopedic surgery under general anesthesia are planned to be enrolled and randomized into the HSK21542 group, morphine group, and placebo group.
- Conditions
- Postoperative Pain Management
- Being tested
- HSK21542, Placebo, morphine
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HSK21542Drug
Patients administrated with HSK21542
PlaceboDrug
Patients administrated with placebo
morphineDrug
Patients administrated with morphine
| Study group | Role | What they receive |
|---|---|---|
| HSK21542 | Experimental | Patients administrated with HSK21542 Receives: Drug: HSK21542 |
| Placebo control | Placebo comparator | Patients administrated with placebo Receives: Drug: Placebo |
| Actice control | Active comparator | Patients administrated with morphine Receives: Drug: morphine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sum of Pain Intensity Differences (SPID)
Sum of Pain Intensity Differences (SPID) of each group
Measured: 48 hours
Secondary outcomes (5)
Proportion of subjects experiencing nausea
Proportion of subjects experiencing nausea of each group
Measured: 48 hours
Proportion of subjects experiencing vomit
Proportion of subjects experiencing vomit of each group
Measured: 48 hours
Sum of Pain Intensity Differences (SPID) in other time frame
Sum of Pain Intensity Differences (SPID) in other time frame
Measured: 0-8 hours, 0-24 hours, 24-48 hours
Number of times rescue analgesic medications were administered.
Number of times rescue analgesic medications were administered.
Measured: 48 hours
Total morphine consumption
Total morphine consumption of each group
Measured: 48 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Sep 2025
- Study start5 Aug 2025
- Primary completion24 Feb 2026
- Study completion24 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postoperative Pain ManagementStudies of the same condition, open and under way.
- More trials run by Haisco Pharmaceutical Group Co., Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 405 participants (actual)
Sponsor and investigators
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07186426
- Sponsor's protocol ID
- HSK21542-305
- Status last verified
- Sep 2025
- First submitted
- 4 Sep 2025
- Last updated
- 26 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-Center, Randomized, Double-Blind, Placebo/Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HSK21542 Injection for Postoperative Pain Treatment in Orthopedic Surgery
- ClinicalTrials.gov ID
- NCT07186426
- Acronym / sponsor ID
- HSK21542-305
- Conditions
- Postoperative Pain Management
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 405 participants (actual)
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 5 Aug 2025 (actual)
- Primary completion
- 24 Feb 2026 (actual)
- Study completion
- 24 Feb 2026 (actual)
- First posted
- 22 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multi-center, randomized, double-blind, placebo/active-controlled study. 405 subjects undergoing orthopedic surgery under general anesthesia are planned to be enrolled and randomized into the HSK21542 group, morphine group, and placebo group.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| HSK21542 | Experimental | Drug: HSK21542Patients administrated with HSK21542 |
| Placebo control | Placebo comparator | Drug: PlaceboPatients administrated with placebo |
| Actice control | Active comparator | Drug: morphinePatients administrated with morphine |
Who may qualify
- Ages
- 18 to 74 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- 18 years old ≤ age ≤74 years old, regardless of gender;
- 18 kg/m2≤BMI≤32 kg/m2，meet the weight range specified in the protocol；
- American Society of Anesthesiologists (ASA) grade ⅰ-ⅲ;
- Accept hip replacement under general anesthesia;
- Within 4 hours after the end of surgery, NRS≥4 in the resting state at any time;
Key exclusion criteria (11 listed)
- Patients with allergy to opioids or any component of the trial drug；
- Patients with a history of severe cardiovascular and cerebrovascular diseases, ,and psychiatric disorders;
- Last use of opioid or non-opioid analgesics less than 5 half-lives or the duration of drug efficacy prior to randomization; use of drugs with unclear half-lives that may affect analgesic efficacy within 7 days prior to randomization, or last use of drugs affecting analgesic efficacy less than 5 half-lives prior to randomization, as well as Chinese herbal medicines or proprietary Chinese medicines deemed by the investigator as potentially impacting the evaluation of efficacy and safety；
- Continuous use of opioid analgesics for more than 7 days for any reason within 30 days prior to screening;
- Laboratory test results during the screening period meeting any of the following criteria: 1) Significantly abnormal hematology results; 2) Significantly abnormal prothrombin time test results; 3) Significantly abnormal liver or kidney function; 4) Significantly abnormal fasting blood glucose;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HSK21542Patients administrated with HSK21542 | Drug | HSK21542 |
| PlaceboPatients administrated with placebo | Drug | Placebo control |
| morphinePatients administrated with morphine | Drug | Actice control |
Primary outcome
Sum of Pain Intensity Differences (SPID)
Time frame: 48 hours
Sum of Pain Intensity Differences (SPID) of each group
5 secondary outcomes
Proportion of subjects experiencing nausea
Time frame: 48 hours
Proportion of subjects experiencing vomit
Time frame: 48 hours
Sum of Pain Intensity Differences (SPID) in other time frame
Time frame: 0-8 hours, 0-24 hours, 24-48 hours
Number of times rescue analgesic medications were administered.
Time frame: 48 hours
Total morphine consumption
Time frame: 48 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Postoperative Pain Management
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
Active, not recruiting
Efficacy of Laparoscopic-Assisted TAP Block in Laparoscopic Appendectomy
Appendectomy, Laparoscopic, Blockades Neuromuscular
RecruitingPhase 4
Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy
Femoracetabular Impingement, Hip Arthroscopy
RecruitingObservational study
Cryo NerVe Block Extremity AmputatioN RegIStry for Post Operative and pHantom Limb Pain
Amputation, Amputation of Lower Limb
Recruiting
Conditioned Open Label Placebo for Postoperative Pain Management
Pain, Postoperative
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing HSK21542 and morphine in people with Postoperative Pain Management, run by Haisco Pharmaceutical Group Co., Ltd. at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sum of Pain Intensity Differences (SPID) (time frame: 48 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2026.